


Design, Synthesis, and Characterization of α -Ketoheterocycles That Additionally Target the Cytosolic Port Cys269 of Fatty Acid Amide Hydrolase

Katerina Otrubova,^{†,§} Benjamin F. Cravatt,^{‡,§} and Dale L. Boger^{*,†,§}

[†]Department of Chemistry, [‡]Chemical Physiology, and [§]The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States

S Supporting Information

ABSTRACT: A series of α -ketooxazoles incorporating electrophiles at the C5 position of the pyridyl ring of **2** (OL-135) and related compounds were prepared and examined as inhibitors of fatty acid amide hydrolase (FAAH) that additionally target the cytosolic port Cys269. From this series, a subset of the candidate inhibitors exhibited time-dependent FAAH inhibition and noncompetitive irreversible inactivation of the enzyme, consistent with the targeted Cys269 covalent alkylation or addition, and maintained or enhanced the intrinsic selectivity for FAAH versus other serine hydrolases. A preliminary in vivo assessment demonstrates that these inhibitors raise endogenous brain levels of anandamide and other FAAH substrates upon intraperitoneal (i.p.) administration to mice, with peak levels achieved within 1.5–3 h, and that the elevations of the signaling lipids were maintained >6 h, indicating that the inhibitors effectively reach and remain active in the brain, inhibiting FAAH for a sustained period.



INTRODUCTION

Because of the therapeutic potential of inhibiting fatty acid amide hydrolase (FAAH)^{1,2} for the treatment of pain,^{3,4} inflammatory,⁵ or sleep disorders,⁶ there is a continuing interest in the development of selective inhibitors of the enzyme.⁷ The distribution of FAAH is consistent with its role in regulating signaling fatty acid amides^{8–10} including anandamide (**1a**)¹¹ and oleamide (**1b**)^{12,13} at their sites of action (Figure 1). Although FAAH is a member of the amidase signature family of serine hydrolases for which there are a number of prokaryotic enzymes, it is the only well-characterized mammalian enzyme bearing the family's unusual Ser–Ser–Lys catalytic triad.^{14,15}




Figure 1. Substrates of fatty acid amide hydrolase.

Early studies following the initial identification of the enzyme led to the disclosure of a series of substrate-inspired inhibitors that were used to characterize the enzyme as a serine hydrolase.^{16–22} Subsequent studies disclosed several classes of inhibitors that provide opportunities for the development of inhibitors with therapeutic potential. These include the reactive aryl carbamates and ureas^{23–31} that irreversibly carbamylate the FAAH active site catalytic serine.³² A second, and one of the earliest classes, is the α -ketoheterocycle-based inhibitors^{33–44} that bind to FAAH by reversible hemiketal formation with the active site catalytic serine. Many of these reversible, competitive inhibitors have been shown to be selective for FAAH versus other mammalian serine hydrolases as well as efficacious analgesics in vivo.^{44,45} In these studies, **2** (OL-135)³⁶ emerged as a potent (K_i = 4.7 nM)³⁶ and selective (>60–300 fold)¹⁹ prototypical FAAH inhibitor that induces analgesia and increases endogenous anandamide levels.⁴⁵ It lacks significant off-site target activity, does not bind cannabinoid (CB1 or CB2) or vanilloid (TRP) receptors, and does not significantly inhibit common P450 metabolism enzymes or the human ether-a-go-go related gene product (hERG). The analgesic effects of **2** are observed without the respiratory depression or chronic dosing desensitization characteristic of opioid administration or the increased feeding and decreased motor control characteristic of cannabinoid (CB) agonist administration.⁴⁵ It possesses a relatively short duration of in vivo activity relative to irreversible inhibitors, although further conformational constraints in the C2 acyl chain of **2** have provided inhibitors that are not only orally active but also exhibit extended durations of in vivo activity.⁴⁴

Received: November 25, 2013

Published: January 23, 2014

Complementary to a series of systematic structure–activity relationship (SAR) studies on **2** exploring substitution of the central oxazole, the C2 acyl side chain, and the central heterocycle,^{33–46} the X-ray characterization of inhibitor-bound complexes defined key features that impact inhibitor affinity and selectivity.^{47–50} These include not only the Ser241 hemiketal formation with the inhibitor electrophilic carbonyl and its interaction with the enzyme oxyanion hole but also an unusual Ser217-mediated OH– π H-bond to the activating heterocycle and the key anchoring interaction of the terminal phenyl group of the C2 acyl chain. The structural studies also revealed that Cys269 is located adjacent to C5 of the inhibitor pyridine substituent, which in turn is engaged in a series of intricate interactions in the enzyme cytosolic port.⁵¹ Herein, we report results of a systematic study of candidate inhibitors containing modifications at the pyridyl C5-position of **2** and related inhibitors that in principle could covalently trap this proximal Cys269 to provide inhibitors that alkylate or cross-link the FAAH active site. In turn, this could be expected to enhance their potency, potentially enhance their selectivity, and extend their in vivo duration of action (Figure 2). Herein, we detail the systematic inhibitor modifications that led to the discovery and

characterization of such inhibitors⁵² and the unexpected trends that the additional strategically placed electrophiles display.

RESULTS AND DISCUSSION

Chemistry. The series 1 analogues (**3–22**) were accessed from 5-(tributylstannyl)oxazole **1e**³⁶ by Stille coupling⁵³ with the appropriate 2-chloro- or 2-bromopyridine (Scheme 1). This was followed typically by TBS ether deprotection (Bu_4NF) and oxidation of the liberated alcohol with Dess–Martin periodinane (DMP)⁵⁴ to provide the corresponding α -ketoheterocycles: **3**, **7**, **9**, **14**, and **18–22**. The remaining inhibitors were accessed by further modification of the pyridyl C5 substituent (Scheme 1).

The second series, in which the pyridine of **2** is replaced with an alkyl linker to the pendant electrophile, was accessed by Sonogashira coupling of 5-bromooxazole **1f**⁴³ with the appropriate alkyne (Scheme 2). The alkyne intermediate was reduced to the corresponding alkane with H_2 and palladium on carbon or palladium hydroxide. This was followed by TBS ether deprotection (Bu_4NF) and oxidation of the liberated alcohol with Dess–Martin periodinane (DMP) to yield the series 2 C5-substituted oxazoles: **23** and **28**. Further elaboration of the terminal electrophile (R group) yielded the remaining compounds: **24–27** and **29–32**.

Enzyme Inhibition. The initial characterization of the candidate inhibitors and their comparison with **2** was conducted using purified recombinant rat FAAH (rFAAH) expressed in *Escherichia coli*⁵⁵ at 20–23 °C as previously disclosed.³⁸ The initial rates of hydrolysis (>10–20% reaction) were monitored using enzyme concentrations below the initially measured K_i values by following the breakdown of ^{14}C -oleamide, and K_i values were established as previously described (Dixon plot).

Series 1 was developed directly on the basis of **2** ($K_i = 4.7 \text{ nM}$), placing a potential thiol-capturing electrophile at the 5-position of the pyridine ring (**5–8**, **11**, **12**, **14**, and **16–22**). Thioesters **5** and **16** were expected to be the most straightforward traps for the Cys269 thiol by thioester exchange. Without preincubation of the inhibitors with the enzyme, these inhibitors along with their precursors (**3–22**) were tested for binding and inhibition of rFAAH (Figure 3). All display potencies similar to **2**, exhibiting K_i values in the low nanomolar range. In series 2, the pyridine ring was replaced by an alkyl chain of appropriate length capped with the thiol-engaging moiety. As modeled, this flexible linker is able to reach through the cytosolic pocket and place the potentially reactive electrophile proximal to Cys269. Like the series 1 inhibitors and without preincubation with the enzyme, all series 2 inhibitors exhibited effective FAAH inhibition with potencies that approach or match that of **2** (Figure 3).

Time-Dependent Enzyme Inhibition. Because the Cys269 alkylation was expected to be slow relative to the rapid hemiketal formation, the time-dependent inhibition of FAAH was examined. This was accomplished by preincubation of the inhibitors with recombinant rFAAH for a period of 1–6 h. As previously observed, reversible, competitive inhibitor **2** does not display time-dependent inhibition of FAAH, and its K_i value remains unchanged with the enzyme–inhibitor preincubation times of 0–6 h (Figure 4). In contrast, a select subset of inhibitors (**11**, **14**, **17**, and **20–22**) in series 1 exhibited significant increases in potency, displaying 2–20-fold improvements in K_i over the same time period, consistent with slow irreversible inhibition of FAAH. Surprisingly, thioesters **5** or **16** did not exhibit this time-dependent increase in enzyme inhibition potency. Similarly, chloride **12** was found to be relatively nonpotent and insensitive to preincubation with the enzyme, whereas the corresponding






Figure 2. Inhibitor series examined.

Scheme 1



bromide **11** was initially more potent and exhibited the most pronounced time-dependent increase in potency of all inhibitors. Both nitrile **7** and its imidate **8**, where the candidate electrophile is attached directly to the pyridyl ring, did not display time-

Scheme 2



dependent increases in potency, whereas both the homologated nitrile **14** and its imide **17**, where a methylene spacer separates the electrophile and pyridyl ring, did exhibit increases in potency with the enzyme–inhibitor preincubation. Of the series of inhibitors that might be expected to serve as Michael acceptors for a thiol conjugate addition (**18–22**), including the α,β -unsaturated ester **18** and nitrile **19**, only those bearing the weaker activating substituents (**20–22** vs **18** and **19**) that would be expected to react slower and to be intrinsically less reversible displayed the exceptionally potent and time-dependent FAAH inhibition improvements. Notably and throughout this series, it was not the anticipated electrophiles that exhibited the time-dependent inhibition of FAAH characteristic of a slow irreversible inhibitor, but rather it was a less-well-recognized alternative (**14** and **17** vs **16**, **11** vs **12**, and **20–22** vs **18–19**). Finally, no inhibitor in series 2 that bears the flexible linker to the second electrophile displayed the time-dependent increases in potency, indicating that the conformationally restricted place-





Figure 3. Enzyme inhibition.

ment of the second electrophile is important to observation of the targeted alkylation. For the inhibitors that displayed time-dependent increases in inhibitor potency, enzyme activity did not recover after this time period and is indicative of irreversible enzyme inhibition.

Lineweaver–Burk Kinetic Analysis. The compounds that demonstrated time-dependent improvements in potency were further investigated by Lineweaver–Burk kinetic analysis. In previous studies, α -ketoheterocycle inhibitors including **2** were shown to display well-behaved competitive, reversible inhibition kinetics. Despite expectations but consistent with the lack of time-dependent FAAH inhibition, Lineweaver–Burk kinetic analysis of thioesters **5**, **16**, and **25** after 3 h preincubation with the enzyme confirmed that they also behave as reversible, competitive inhibitors, analogous to **2** and related α -ketoheterocycle inhibitors (Figure 5). Thus, despite the expectations of a

Figure 4. Time-dependent inhibition. K_i values were measured after 0–6 h inhibitor preincubation with rFAAH.

facile transthioesterification with Cys269, the thioesters exhibit enzyme inhibition characteristic of reversible inhibitors, suggesting that reaction with Cys269 does not occur.⁵⁶




Figure 5. Lineweaver–Burk kinetic analysis of **5**, **16**, and **25** demonstrate reversible, competitive inhibition.

Significantly, thioesters **5** and **25** were recovered unchanged from the assay buffer (6 h) and from enzymatic assays (**5**), indicating that they are not undergoing chemical hydrolysis or transient enzyme adduct formation and subsequent hydrolysis under the conditions of the assay.

In contrast, the inhibitors that demonstrated a time-dependent increase in inhibitor potency also exhibited noncompetitive inhibition of FAAH when preincubated with the enzyme for 3 h prior to Lineweaver–Burk kinetic analysis (Figure 6). This is expected of irreversible enzyme inhibition and consistent with Cys269 alkylation or addition to the pendant electrophile. In the case of **11**, this entails Cys269 thiol nucleophilic displacement of the benzylic bromide to provide the corresponding thioether, and its structure has been confirmed by X-ray analysis of the inhibitor bound to FAAH.⁵² The noncompetitive enzyme

inhibition presumably entails thiol nucleophilic addition to the electrophile to provide the Cys269-linked thioimide for **14** and **17**, and it presumably involves an apparent irreversible thiol conjugate addition to **20–22**. Interestingly, both the α,β -unsaturated nitrile **19** and ester **18**, which do not exhibit time-dependent increases in inhibitor activity or the potent K_i values consistent with irreversible inhibition, displayed mixed kinetics, exhibiting competitive inhibition at low inhibitor concentrations and noncompetitive inhibition at high concentrations. Presumably, this indicates that the thiol conjugate addition products derived from **18** and **19** are either formed less effectively or, more likely, that they may be sufficiently reversible at 23 °C to less effectively trap Cys269 as an apparent irreversible inhibitor of the enzyme.

Irreversible Enzyme Inhibition. Dialysis dilution (4 °C, 18 h, 370-fold) of the FAAH-inhibitor mixture following 3 h of preincubation with **2** restored full enzyme activity, consistent with its reversible enzyme inhibition, whereas the mixtures containing **11**, **14**, and **17–22** remained relatively unchanged, failing to restore FAAH activity, indicative of irreversible enzyme inhibition under the conditions monitored (4 °C, pH 9, Figure 7). It is notable that **14** and **17** (not shown), which presumably form a Cys269 thioimide adduct, do not appear to be even slowly reversible under these conditions. Similarly, **20–22** displayed irreversible inhibition of FAAH, consistent with their time-dependent, noncompetitive enzyme inhibition. Interestingly, dialysis dilution at 4 °C also did not restore enzyme activity with both the α,β -unsaturated nitrile **19** and ester **18**, which do not exhibit time-dependent FAAH inhibition and displayed concentration-dependent mixed competitive/noncompetitive




Figure 6. Lineweaver–Burk analysis demonstrates noncompetitive FAAH inhibition for (A) **11**, (B) **14**, (C) **17**, (D) **20**, (E) **21**, and (F) **22**.




Figure 7. Dialysis dilution of inhibitor–FAAH mixtures illustrates reversible inhibition by **2** and establishes irreversible FAAH inhibition by **11**, **14**, and **17–22**. After 3 h preincubation of purified recombinant rat FAAH with compounds at concentrations that result in inhibition of ca. 80% enzyme activity (22 °C; 3 h; 100 nM, **2**; 80 nM, **11** and **14**; 100 nM, **18** and **19**; 150 nM, **20**; and 80 nM, **21** and **22**), and following measurement of residual enzyme activity, dialysis dilution (4 °C, 18 h, 370-fold dilution) of the mixtures resulted in nearly full recovery of enzyme activity for **2** but little or no recovery of enzyme activity for **11**, **14**, and **17–22** under the conditions monitored (4 °C, pH 9); conducted in triplicate and reported as the percent enzyme inhibition \pm SD.

kinetics in the Lineweaver–Burk analysis at 23 °C. This suggests that their inhibition of FAAH following the 3 h incubation (22 °C) is not reversible at 0 °C. Unfortunately, the reversibility of **18** and **19** at 23 °C could not be established because of the instability of FAAH at 23 °C over the dialysis time frame.

Inhibitor Selectivity. The selectivity of the time-dependent, irreversible FAAH inhibitors **17** and **20–22** were examined along with **11** and **14** that were recently disclosed⁵² using activity-based protein profiling (ABPP) of the serine hydrolases.⁵⁷ ABPP methods permit the testing of serine hydrolases in their native state and eliminate the need for their recombinant expression, purification, and the development of specific substrate assays. Because inhibitors are screened against many enzymes in the proteome in parallel, both relative potency and selectivity can be simultaneously evaluated. Previous studies^{19,37,52} have shown that the α -ketoheterocycle class of inhibitors are selective for FAAH, although four enzymes have emerged as potential competitive targets: triacylglycerol hydrolase (TGH), $\alpha\beta$ hydrolase containing domain 6 (ABHD6), monoacylglycerol lipase (MAGL), and the membrane-associated hydrolase KIAA1363. Each inhibitor was tested for its effects on the fluorophosphonate (FP)-rhodamine probe labeling of serine hydrolases in the mouse brain (contains KIAA1363, MAGL, and ABHD6) and heart membrane (contains TGH) proteome at concentrations ranging from 10 nM to 100 μ M. The selectivity assessments were conducted following 6 h inhibitor incubation with the proteomes and all inhibitors showed superb selectivity for FAAH over KIAA1363 and ABHD6 ($>10^4$ -fold), excellent selectivity over MAGL (>200 -fold), and good selectivity over TGH (Figure 8).

Preliminary in Vivo Characterization. In initial efforts to screen for in vivo inhibition of FAAH and its subsequent pharmacological effects, the set of inhibitors displaying the time-dependent, irreversible FAAH inhibition (**11**, **14**, **17**, and **20–22**) were examined alongside of **2** for their ability to increase the endogenous levels of a series of lipid amide signaling molecules that are substrates for FAAH in both the brain (CNS effect) and liver (peripheral effect, not shown). Thus, the effects of the

inhibitor	IC ₅₀ (nM)				
	FAAH	TGH	KIAA1363	MAGL	ABHD6
11	30	400	>100000	8000	>100000
14	<10	200	>100000	1000	95000
17	<10	500	>100000	>100000	>100000
20	270	760	>100000	>100000	>100000
21	80	460	>100000	>100000	>100000
22	<10	520	>100000	2000	97000

Figure 8. ABPP selectivity screen in mouse brain membrane proteome (1 mg/mL) with FP-rhodamine (100 nM), $n = 2–4$. Inhibitor preincubation with the proteome was conducted for 6 h.

inhibitors on the endogenous levels of the FAAH substrates anandamide (AEA), oleoyl ethanolamide (OEA), and palmitoyl ethanolamide (PEA) were measured. Notably, it is the increase in endogenous levels of anandamide and its subsequent action at cannabinoid (CB1 and CB2) receptors that are thought to be responsible for the analgesic and anti-inflammatory effects of FAAH inhibitors. The effects were established 3 h following intraperitoneal (i.p.) administration of inhibitor in three mice per time point for an initial screen (30 mg/kg). Significantly, increases in endogenous levels of anandamide in the brain requires $>90\%$ inhibition of FAAH for in vivo enzyme inhibition.⁵⁸ With the exception of imidate **17**, which matched the increased anandamide levels observed with **2** after 3 h, each of the additional inhibitors proved to be roughly equivalent (**11**, **14**, and **20** $>$ **21** and **22**), increasing anandamide levels approximately 2-fold over that of **2** and approximately 3-fold over vehicle treatment (Figure 9).

With PEA and OEA, which show significant enhancements in endogenous levels with partial enzyme inhibition and are less sensitive to the extent of FAAH inhibition, all of the inhibitors that displayed time-dependent, irreversible FAAH inhibition matched or exceeded the activity of **2**, producing elevations of 3–12-fold over vehicle. Of these, both bromide **11** and nitrile **14** exhibited the largest increases. As a result, more detailed dose- and time-dependent studies of **11** and **14** were conducted as reported elsewhere.⁵² The results of these studies revealed that they cause accumulation of all three lipid amides in the brain with peak levels achieved within 1.5–3 h, that these elevations exceed those achieved with the reversible inhibitor **2**, that these elevations are maintained >6 h (vs 2–3 h for **2**), consistent with irreversible enzyme inhibition, and that they exhibit long acting in vivo activity in a mouse model of neuropathic pain.⁵²

CONCLUSIONS

The design, synthesis, and characterization of α -ketoheterocycles that additionally target the remote Cys269 nucleophile found in the cytosolic port of FAAH⁵⁹ provided inhibitors that slowly react with the enzyme nucleophile, effectively providing time-dependent, irreversible inhibitors of the enzyme that maintain or enhance their selectivity for FAAH over other serine hydrolases. The electrophiles capable of targeting Cys269 were incorporated as a CS substituent on the pyridyl group of the 5-(pyrid-2-yl) oxazole of **2** and ranged from the reactive benzylic bromide **11** to the otherwise benign nitrile **14**. The irreversible inhibitors of FAAH displayed an expected sensitivity to the position of the electrophile introduction, but those that were successful exhibited surprising trends in apparent reactivity toward Cys269 that would not be easily predicted. A preliminary in vivo characterization of the identified irreversible FAAH




Figure 9. Lipid levels in the brain 3 h post inhibitor administration (i.p., 30 mg/kg, $n = 3$).

inhibitors confirmed their ability to raise endogenous brain levels of the enzyme substrates, including anandamide, in mice to a greater extent (>2-fold) and for a longer duration (>6 h) than the reversible α -ketoheterocycles on which they are based. Two of these (11 and 14) were characterized in greater detail, as reported elsewhere, along with their long acting *in vivo* efficacy in a mouse model of neuropathic pain.⁵²

EXPERIMENTAL SECTION

FAAH Inhibition. ¹⁴C-labeled oleamide was prepared from ¹⁴C-labeled oleic acid as described.¹³ The truncated rat FAAH (rFAAH) was expressed in *E. coli* and purified as described,⁵⁵ and the purified

recombinant rFAAH was used in the inhibition and reversibility assays unless otherwise indicated. The purity of each tested compound (>95%) was determined on an Agilent 1100 LC/MS instrument using a ZORBAX SB-C18 column (3.5 mm, 4.6 mm \times 50 mm, with a flow rate of 0.75 mL/min and detection at 220 and 253 nm) with a 10–98% acetonitrile/water/0.1% formic acid gradient (two different gradients).

The inhibition assays were performed as described.³⁶ The enzyme reaction was initiated by mixing 1 nM rFAAH (800, 500, or 200 pM rFAAH for inhibitors with $K_i \leq 1$ –2 nM) with 20 μ M ¹⁴C-labeled oleamide in 500 μ L of reaction buffer (125 mM TrisCl, 1 mM EDTA, 0.2% glycerol, 0.02% Triton X-100, and 0.4 mM Hepes, pH 9.0) at room temperature in the presence of three different concentrations of inhibitor. The enzyme reaction was terminated by transferring 20 μ L of the reaction mixture to 500 μ L of 0.1 N HCl at three different time points. The ¹⁴C-labeled oleamide (substrate) and oleic acid (product) were extracted with EtOAc and analyzed by TLC as detailed.¹³ The K_i of the inhibitor was calculated using a Dixon plot. Lineweaver–Burk kinetic analysis was performed as described,³⁶ confirming competitive, reversible inhibition for 5, 16, and 25 and noncompetitive inhibition for 11, 14, 17, and 20–22 (Figures 5 and 6).

Reversibility of FAAH Inhibition (Dialysis). The reversibility of FAAH inhibition by 2, 11, 14, and 17–22 was assessed by dialysis dilution using purified recombinant rFAAH. The enzyme was placed in 15 mL of FAAH assay buffer (125 mM Tris, 1 mM EDTA, 0.2% glycerol, 0.02% Triton X-100, and 0.4 mM Hepes, pH 9.0). A 3 mL aliquot of membrane homogenate was used for each sample dialyzed. The dialysis experiment was performed in the predialysis mix at or near the apparent IC_{50} . The final assay inhibitor concentrations used were 100 nM, 2, 18, and 19; 80 nM, 11, 14, 21, and 22; and 150 nM, 20. Samples were preincubated with the enzyme for 3 h at room temperature (22 $^{\circ}$ C) before 300 μ L was removed and assayed in triplicate in a FAAH activity assay. The remaining sample (2.7 mL) was injected into a dialysis cassette employing a 10 000 MW cutoff membrane. The mixture was dialyzed against 1 L of PBS at 4 $^{\circ}$ C on a stir plate for 18 h. The postdialysis FAAH activity was assessed by assaying 300 μ L samples taken from the dialysis cassettes in triplicate. FAAH activity is expressed as a percentage of vehicle-treated FAAH (DMSO alone) and is shown in Figure 7.

Competitive ABPP of FAAH Inhibitors with FP-Rhodamine. Mouse tissues were Dounce-homogenized in PBS buffer (pH 8.0), and membrane proteomes were isolated by centrifugation at 4 $^{\circ}$ C (100 000g, 45 min), washed, resuspended in PBS buffer, and adjusted to a protein concentration of 1 mg/mL. Proteomes were preincubated with inhibitors (10–100 000 nM, DMSO stocks) for 6 h and then treated with FP-rhodamine (100 nM, DMSO stock) at room temperature for 10 min. Reactions were quenched with SDS-PAGE loading buffer, subjected to SDS-PAGE, and visualized in-gel using a flatbed fluorescence scanner (MiraBio). Labeled proteins were quantified by measuring integrated band intensities (normalized for volume); control samples (DMSO alone) were considered to have 100% activity. IC_{50} values ($n = 2$ –4) were determined from dose–response curves using Prism software and are reported in Figure 8.

In Vivo Pharmacodynamic Studies with Inhibitors. Inhibitors were prepared as a saline–emulphor emulsion for intraperitoneal (i.p.) administration by vortexing, sonicating, and gently heating neat compound directly in an 18:1:1 v/v/v solution of saline/ethanol/emulphor. Male C57Bl/6J mice (<6 months old, 20–28 g) were administered inhibitors in saline–emulphor emulsion or an 18:1:1 v/v/v saline/emulphor/ethanol vehicle i.p. at a volume of 10 μ L/g weight. After the indicated amount of time (1, 3, or 6 h), mice ($n = 3$ for each compound at each time point) were anesthetized with isoflurane and killed by decapitation. Total brains (~400 mg) and a portion of the liver (~100 mg) were removed and flash frozen in liquid N₂. Animal experiments were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of The Scripps Research Institute.

Measurement of Brain Lipids. Tissue was weighed and subsequently Dounce-homogenized in 2:1:1 v/v/v CHCl₃/MeOH/Tris pH 8.0 (8 mL) containing standards for lipids (50 pmol of *d*₄-PEA, 2 pmol of *d*₄-AEA, and 10 nmol of pentadecanoic acid). The mixture was

vortexed and then centrifuged (1400g, 10 min). The organic layer was removed, dried under a stream of N₂, and resolubilized in 2:1 v/v CHCl₃/MeOH (120 μ L), and 10 μ L of this resolubilized lipid was injected onto an Agilent G6410B QQQ instrument. LC separation was achieved with a Gemini reverse-phase C18 column (5 μ m, 4.6 mm \times 50 mm, Phenomenex) together with a precolumn (C18, 3.5 μ m, 2 mm \times 20 mm). Mobile phase A was composed of 95:5 v/v H₂O/MeOH, and mobile phase B was composed of 65:35:5 v/v/v i-PrOH/MeOH/H₂O. The flow rate for each run started at 0.1 mL/min with 0% B. At 5 min, the solvent was immediately changed to 60% B with a flow rate of 0.4 mL/min and increased linearly to 100% B over 10 min. This was followed by an isocratic gradient of 100% B for 5 min at 0.5 mL/min before equilibrating for 3 min at 0% B at 0.5 mL/min (23 min total per sample). MS analysis was performed with an electrospray ionization (ESI) source. The following MS parameters were used to measure the indicated metabolites in positive mode (precursor ion, product ion, collision energy in V): AEA (348, 62, 11), OEA (326, 62, 11), PEA (300, 62, 11), *d*₄-AEA (352, 66, 11), and *d*₄-PEA (304, 62, 11). The capillary was set to 4 kV, the ionization source was set to 100 V, and the delta EMV was set to 0. Lipids were quantified by measuring the area under the peak in comparison to the standards (*n* = 3 for each inhibitor at each time point).

■ ASSOCIATED CONTENT

■ Supporting Information

Full experimental details and characterization of the candidate inhibitors, inhibitor purities, and enzyme inhibition measurement standard deviations for Figures 3, 4, and 8. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Phone: 858-784-7522. Fax: 858-784-7550. E-mail: boger@scripps.edu.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We gratefully acknowledge the financial support of the National Institutes of Health (DA015648, D.L.B.; DA017259, B.F.C.).

■ ABBREVIATIONS USED

AA, arachidonic acid; ABHD6, $\alpha\beta$ hydrolase containing domain 6; ABPP, activity-based protein profiling; AEA, anandamide; CB, cannabinoid; DMP, Dess–Martin periodinane; FAAH, fatty acid amide hydrolase; i.p., intraperitoneal; MAGL, monoacylglycerol lipase; OEA, oleoyl ethanolamide; PEA, palmitoyl ethanolamide; TBS, *tert*-butyldimethylsilyl; TGH, triacylglycerol hydrolase

■ REFERENCES

- (1) (a) Cravatt, B. F.; Lichtman, A. H. Fatty Acid Amide Hydrolase: An Emerging Therapeutic Target in the Endocannabinoid System. *Curr. Opin. Chem. Biol.* **2003**, *7*, 469–475. (b) Lambert, D. M.; Fowler, C. J. The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications. *J. Med. Chem.* **2005**, *48*, 5059–5087. (c) Ahn, K.; McKinney, M. K.; Cravatt, B. F. Enzymatic Pathways that Regulate Endocannabinoid Signaling in the Nervous System. *Chem. Rev.* **2008**, *108*, 1687–1707. (d) Ahn, K.; Johnson, D. S.; Cravatt, B. F. Fatty Acid Amide Hydrolase as a Potential Therapeutic Target for the Treatment of Pain and CNS Disorders. *Expert Opin. Drug Discovery* **2009**, *4*, 763–784.
- (2) (a) Cravatt, B. F.; Giang, D. K.; Mayfield, S. P.; Boger, D. L.; Lerner, R. A.; Gilula, N. B. Molecular Characterization of an Enzyme that Degrades Neuromodulatory Fatty Acid Amides. *Nature* **1996**, *384*, 83–87. (b) Giang, D. K.; Cravatt, B. F. Molecular Characterization of

Human and Mouse Fatty Acid Amide Hydrolases. *Proc. Natl. Acad. Sci. U.S.A.* **1997**, *94*, 2238–2242.

(3) (a) Cravatt, B. F.; Demarest, K.; Patricelli, M. P.; Bracey, M. H.; Giang, D. K.; Martin, B. R.; Lichtman, A. H. Supersensitivity to Anandamide and Enhanced Endogenous Cannabinoid Signaling in Mice Lacking Fatty Acid Amide Hydrolase. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 9371–9376. (b) Lichtman, A. H.; Shelton, C. C.; Advani, T.; Cravatt, B. F. Mice Lacking Fatty Acid Amide Hydrolase Exhibit a Cannabinoid Receptor-Mediated Phenotypic Hypoalgesia. *Pain* **2004**, *109*, 319–327.

(4) Cravatt, B. F.; Saghatelian, A.; Hawkins, E. G.; Clement, A. B.; Bracey, M. H.; Lichtman, A. H. Functional Disassociation of the Central and Peripheral Fatty Acid Amide Signaling Systems. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 10821–10826.

(5) Karsak, M.; Gaffal, E.; Date, R.; Wang-Eckhardt, L.; Rehnelt, J.; Petrosino, S.; Starowicz, K.; Steuder, R.; Schlicker, E.; Cravatt, B. F.; Mechoulam, R.; Buettner, R.; Werner, S.; Di Marzo, V.; Tueting, T.; Zimmer, A. Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System. *Science* **2007**, *316*, 1494–1497.

(6) (a) Huitrón-Reséndiz, S.; Gombart, L.; Cravatt, B. F.; Henriksen, S. J. Effect of Oleamide on Sleep and Its Relationship to Blood Pressure, Body Temperature, and Locomotor Activity in Rats. *Exp. Neurol.* **2001**, *172*, 235–243. (b) Huitrón-Reséndiz, S.; Sanchez-Alavez, M.; Wills, D. N.; Cravatt, B. F.; Henriksen, S. J. Characterization of the Sleep-Wake Patterns in Mice Lacking Fatty Acid Amide Hydrolase. *Sleep* **2004**, *27*, 857–865.

(7) (a) Otrubova, K.; Ezzili, C.; Boger, D. L. The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). *Bioorg. Med. Chem. Lett.* **2011**, *21*, 4674–4685. (b) Deng, H. F. Recent Advances in the Discovery and Evaluation of Fatty Acid Amide Hydrolase Inhibitors. *Expert Opin. Drug Discovery* **2010**, *5*, 961–993. (c) Seierstad, M.; Breitenbucher, J. G. Discovery and Development of Fatty Acid Amide Hydrolase (FAAH) Inhibitors. *J. Med. Chem.* **2008**, *51*, 7327–7343. (d) Vandevoorde, S. Overview of the Chemical Families of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase Inhibitors. *Curr. Top. Med. Chem.* **2008**, *8*, 247–267.

(8) Ezzili, C.; Otrubova, K.; Boger, D. L. Fatty Acid Amide Signaling Molecules. *Bioorg. Med. Chem. Lett.* **2010**, *20*, S959–S968.

(9) (a) Patricelli, M. P.; Cravatt, B. F. Proteins Regulating the Biosynthesis and Inactivation of Neuromodulatory Fatty Acid Amides. *Vitam. Horm.* **2001**, *62*, 95–131. (b) Egertova, M.; Cravatt, B. F.; Elphick, M. R. Comparative Analysis of Fatty Acid Amide Hydrolase and CB1 Cannabinoid Receptor Expression in the Mouse Brain: Evidence of a Widespread Role for Fatty Acid Amide Hydrolase in Regulation of Endocannabinoid Signaling. *Neuroscience* **2003**, *119*, 481–496.

(10) Boger, D. L.; Fecik, R. A.; Patterson, J. E.; Miyauchi, H.; Patricelli, M. P.; Cravatt, B. F. Fatty Acid Amide Hydrolase Substrate Specificity. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 2613–2616.

(11) (a) Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and Structure of a Brain Constituent that Binds to the Cannabinoid Receptor. *Science* **1992**, *258*, 1946–1949. (b) Martin, B. R.; Mechoulam, R.; Razdan, R. K. Discovery and Characterization of Endogenous Cannabinoids. *Life Sci.* **1999**, *65*, 573–595. (c) Di Marzo, V.; Bisogno, T.; De Petrocellis, L.; Melck, D.; Martin, B. R. Cannabinomimetic Fatty Acid Derivatives: The Anandamide Family and Other Endocannabinoids. *Curr. Med. Chem.* **1999**, *6*, 721–744. (d) Schmid, H. H. O.; Schmid, P. C.; Natarajan, V. N-Acylated Glycerophospholipids and Their Derivatives. *Prog. Lipid Res.* **1990**, *29*, 1–43.

(12) Boger, D. L.; Henriksen, S. J.; Cravatt, B. F. Oleamide: An Endogenous Sleep-Inducing Lipid and Prototypical Member of a New Class of Lipid Signaling Molecules. *Curr. Pharm. Des.* **1998**, *4*, 303–314.

(13) (a) Cravatt, B. F.; Lerner, R. A.; Boger, D. L. Structure Determination of an Endogenous Sleep-Inducing Lipid, *cis*-9-Octadecenamide (Oleamide): A Synthetic Approach to the Chemical Analysis of Trace Quantities of a Natural Product. *J. Am. Chem. Soc.* **1996**, *118*, 580–590. (b) Cravatt, B. F.; Prospero-Garcia, O.; Suizdak, G.; Gilula, N. B.; Henriksen, S. J.; Boger, D. L.; Lerner, R. A. Chemical

Characterization of a Family of Brain Lipids that Induce Sleep. *Science* **1995**, 268, 1506–1509. (c) Lerner, R. A.; Siuzdak, G.; Prospero-Garcia, O.; Henriksen, S. J.; Boger, D. L.; Cravatt, B. F. Cerebrodiene: A Brain Lipid Isolated from Sleep-Deprived Cats. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, 91, 9505–9508.

(14) (a) Patricelli, M. P.; Cravatt, B. F. Fatty Acid Amide Hydrolase Competitively Degrades Bioactive Amides and Esters through a Nonconventional Catalytic Mechanism. *Biochemistry* **1999**, 38, 14125–14130. (b) Patricelli, M. P.; Cravatt, B. F. Clarifying the Catalytic Roles of Conserved Residues in the Amidase Signature Family. *J. Biol. Chem.* **2000**, 275, 19177–19184. (c) Patricelli, M. P.; Lovato, M. A.; Cravatt, B. F. Chemical and Mutagenic Investigations of Fatty Acid Amide Hydrolase: Evidence for a Family of Serine Hydrolases with Distinct Catalytic Properties. *Biochemistry* **1999**, 38, 9804–9812. (d) McKinney, M. K.; Cravatt, B. F. Evidence for Distinct Roles in Catalysis for Residues of the Serine-Serine-Lysine Catalytic Triad of Fatty Acid Amide Hydrolase. *J. Biol. Chem.* **2003**, 278, 37393–37399. (e) Bracey, M. H.; Hanson, M. A.; Masuda, K. R.; Stevens, R. C.; Cravatt, B. F. Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling. *Science* **2002**, 298, 1793–1796.

(15) McKinney, M. K.; Cravatt, B. F. Structure and Function of Fatty Acid Amide Hydrolase. *Annu. Rev. Biochem.* **2005**, 74, 411–432.

(16) (a) Patterson, J. E.; Ollmann, I. R.; Cravatt, B. F.; Boger, D. L.; Wong, C.-H.; Lerner, R. A. Inhibition of Oleamide Hydrolase Catalyzed Hydrolysis of the Endogenous Sleep-Inducing Lipid *cis*-9-Octadecanamide. *J. Am. Chem. Soc.* **1996**, 118, 5938–5945. (b) Koutek, B.; Prestwich, G. D.; Howlett, A. C.; Chin, S. A.; Salehani, D.; Akhavan, N.; Deutsch, D. G. Inhibitors of Arachidonoyl Ethanolamide Hydrolysis. *J. Biol. Chem.* **1994**, 269, 22937–22940.

(17) Patricelli, M. P.; Patterson, J. P.; Boger, D. L.; Cravatt, B. F. An Endogenous Sleep-Inducing Compound Is a Novel Competitive Inhibitor of Fatty Acid Amide Hydrolase. *Bioorg. Med. Chem. Lett.* **1998**, 8, 613–618.

(18) Boger, D. L.; Sato, H.; Lerner, A. E.; Austin, B. J.; Patterson, J. E.; Patricelli, M. P.; Cravatt, B. F. Trifluoromethyl Ketone Inhibitors of Fatty Acid Amide Hydrolase: A Probe of Structural and Conformational Features Contributing to Inhibition. *Bioorg. Med. Chem. Lett.* **1999**, 9, 265–270.

(19) Leung, D.; Hardouin, C.; Boger, D. L.; Cravatt, B. F. Discovering Potent and Selective Reversible Inhibitors of Enzymes in Complex Proteomes. *Nat. Biotechnol.* **2003**, 21, 687–691.

(20) (a) Deutsch, D. G.; Omeir, R.; Arreaza, G.; Salehani, D.; Prestwich, G. D.; Huang, Z.; Howlett, A. Methyl Arachidonoyl Fluorophosphonate: A Potent Irreversible Inhibitor of Anandamide Amidase. *Biochem. Pharmacol.* **1997**, 53, 255–260. (b) Deutsch, D. G.; Lin, S.; Hill, W. A. G.; Morse, K. L.; Salehani, D.; Arreaza, G.; Omeir, R. L.; Makriyannis, A. Fatty Acid Sulfonyl Fluorides Inhibit Anandamide Metabolism and Bind to the Cannabinoid Receptor. *Biochem. Biophys. Res. Commun.* **1997**, 231, 217–221.

(21) Edgmond, W. S.; Greenberg, M. J.; McGinley, P. J.; Muthians, S.; Campbell, W. B.; Hillard, C. J. Synthesis and Characterization of Diazomethylarachidonoyl Ketone: An Irreversible Inhibitor of *N*-Arachidonylethanolamine Amidohydrolase. *J. Pharmacol. Exp. Ther.* **1998**, 286, 184–190.

(22) Du, W.; Hardouin, C.; Cheng, H.; Hwang, I.; Boger, D. L. Heterocyclic Sulfoxide and Sulfone Inhibitors of Fatty Acid Amide Hydrolase. *Bioorg. Med. Chem. Lett.* **2005**, 15, 103–106.

(23) (a) Kathuria, S.; Gaetani, S.; Fegley, D.; Valino, F.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; La Rana, G.; Calignano, A.; Giustino, A.; Tattoli, M.; Palmery, M.; Cuomo, V.; Piomelli, D. Modulation of Anxiety through Blockade of Anandamide Hydrolysis. *Nat. Med.* **2003**, 9, 76–81. (b) Gobbi, G.; Bambico, F. R.; Mangieri, R.; Bortolato, M.; Campolongo, P.; Solinas, M.; Cassano, T.; Morgese, M. G.; Debonnel, G.; Duranti, A.; Tontini, A.; Tarzia, G.; Mor, M.; Trezza, V.; Goldberg, S. R.; Cuomo, V.; Piomelli, D. Antidepressant-Like Activity and Modulation of Brain Monoaminergic Transmission by Blockage of Anandamide Hydrolase. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, 102, 18620–18625. (c) Jayamanne, A.; Greenwood, R.; Mitchell, V. A.; Aslan, S.; Piomelli, D.; Vaughan, C. W. Actions of the FAAH Inhibitor URBS97 in

Neuropathic and Inflammatory Chronic Pain Models. *Br. J. Pharmacol.* **2006**, 147, 281–288.

(24) (a) Mor, M.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Kathuria, S.; Piomelli, D. Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure–Activity Relationships, and Molecular Modeling Studies. *J. Med. Chem.* **2004**, 47, 4998–5008. (b) Biancalani, C.; Giovanni, M. P.; Pieretti, S.; Cesari, N.; Graziano, A.; Vergeli, C.; Cilibrizzi, A.; Di Gianuario, A.; Colucci, M.; Mangano, G.; Garrone, B.; Polezani, L.; Dal Piaz, V. Further Studies on Acylpiperazinyl Alkyl Pyridazinones: Discovery of An Exceptionally Potent, Orally Active, Antinociceptive Agent in Thermally Induced Pain. *J. Med. Chem.* **2009**, 52, 7397–7409.

(25) (a) Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Mor, M.; Rivara, S.; Plazzi, P. V.; Park, C.; Kathuria, S.; Piomelli, D. Design, Synthesis, and Structure–Activity Relationships of Alkylcarbamic Acid Aryl Esters, a New Class of Fatty Acid Amide Hydrolase Inhibitors. *J. Med. Chem.* **2003**, 46, 2352–2360. (b) Tarzia, G.; Duranti, A.; Gatti, G.; Piersanti, G.; Tontini, A.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Mor, M.; Kathuria, S.; Piomelli, D. Synthesis and Structure–Activity Relationships of FAAH Inhibitors: Cyclohexylcarbamic Acid Biphenyl Esters with Chemical Modulation at the Proximal Phenyl Ring. *ChemMedChem* **2006**, 1, 130–139. (c) Clapper, J. R.; Vacondio, F.; King, A. R.; Duranti, A.; Tontini, A.; Silva, C.; Sanchini, S.; Tarzia, G.; Mor, M.; Piomelli, D. A Second Generation of Carbamate-Based Fatty Acid Amide Hydrolase Inhibitors with Improved Activity in vivo. *ChemMedChem* **2009**, 4, 1505–1513.

(26) (a) Ahn, K.; Johnson, D. S.; Fitzgerald, L. R.; Liimatta, M.; Arendse, A.; Stevenson, T.; Lund, E. T.; Nugent, R. A.; Normanbhoy, T.; Alexander, J. P.; Cravatt, B. F. A Novel Mechanistic Class of Fatty Acid Amide Hydrolase Inhibitors with Remarkable Selectivity. *Biochemistry* **2007**, 46, 13019–13030. (b) Johnson, D. S.; Ahn, K.; Kesten, S.; Lazerwith, S. E.; Song, Y.; Morris, M.; Fay, L.; Gregory, T.; Stiff, C.; Dunbar, J. B., Jr.; Liimatta, M.; Beidler, D.; Smith, S.; Nomanbhoy, T. K.; Cravatt, B. F. Benzothiophene Piperazine and Piperidine Urea Inhibitors of Fatty Acid Amide Hydrolase (FAAH). *Bioorg. Med. Chem. Lett.* **2009**, 19, 2865–2869. (c) Ahn, K.; Johnson, D. S.; Mileni, M.; Beidler, D.; Long, J. Z.; McKinney, M. K.; Weerapana, E.; Sadagopan, N.; Liimatta, M.; Smith, S. E.; Lazerwith, S.; Stiff, C.; Kamtekar, S.; Bhattacharya, K.; Zhang, Y.; Swaney, S.; Van Becelaere, K.; Stevens, R. C.; Cravatt, B. F. Discovery and Characterization of a Highly Selective FAAH Inhibitor That Reduces Inflammatory Pain. *Chem. Biol.* **2009**, 16, 411–420. (d) Johnson, D. S.; Stiff, C.; Lazerwith, S. E.; Kesten, S. R.; Fay, L. K.; Morris, M.; Beidler, D.; Liimatta, M. B.; Smith, S. E.; Dudley, D. T.; Sadagopan, N.; Bhattachar, S. N.; Kesten, S. J.; Nomanbhoy, T. K.; Cravatt, B. F.; Ahn, K. Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. *ACS Med. Chem. Lett.* **2011**, 2, 91–96.

(27) (a) Meyers, J. M.; Long, A. S.; Pelc, J. M.; Wang, L. J.; Bowen, J. S.; Walker, C. M.; Schweitzer, A. B.; Madsen, M. H.; Tenbrink, E. R.; McDonald, J.; Smith, E. S.; Foltin, S.; Beidler, F.; Thorarensen, A. Discovery of Novel Spirocyclic Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Part 1: Identification of 7-Azaspiro[3.5]nonane and 1-Oxa-8-azaspiro[4.5]decane as Lead Scaffolds. *Bioorg. Med. Chem. Lett.* **2011**, 21, 6538–6544. (b) Meyers, J. M.; Long, A. S.; Pelc, J. M.; Wang, L. J.; Bowen, J. S.; Schweitzer, A. B.; Wilcox, C. M.; McDonald, J.; Smith, E. S.; Foltin, S.; Rumsey, J.; Yang, S. Y.; Walker, C. M.; Kamtekar, S.; Beidler, F.; Thorarensen, A. Discovery of Novel Spirocyclic Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Part 2: Discovery of 7-Azaspiro[3.5]nonane Urea PF-04862853, An Orally Efficacious Inhibitor of Fatty Acid Amide Hydrolase (FAAH) for Pain. *Bioorg. Med. Chem. Lett.* **2011**, 21, 6545–6553.

(28) (a) Sit, S. Y.; Conway, C.; Bertekap, R.; Xie, K.; Bourin, C.; Burris, K.; Deng, H. Novel Inhibitors of Fatty Acid Amide Hydrolase. *Bioorg. Med. Chem. Lett.* **2007**, 17, 3287–3291. (b) Sit, S. Y.; Conway, C. M.; Xie, K.; Bertekap, R.; Bourin, C.; Burris, K. D. Oxime Carbamates: Discovery of a Series of Novel FAAH Inhibitors. *Bioorg. Med. Chem. Lett.* **2010**, 20, 1272–1277.

- (29) (a) Keith, J. M.; Apocada, R.; Xiao, W.; Seierstad, M.; Pattabiraman, K.; Wu, J.; Webb, M.; Karbarz, M. J.; Brown, S.; Wilson, S.; Scott, B.; Tham, C.-S.; Luo, L.; Palmer, J.; Wennerholm, M.; Chaplan, S.; Breitenbucher, J. G. Thiadiazolopiperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4838–4843. (b) Karbarz, M. J.; Luo, L.; Chang, L.; Tham, C.-S.; Palmer, J. A.; Wilson, S. J.; Wennerholm, M. L.; Brown, S. M.; Scott, B. P.; Apocada, R. L.; Keith, J. M.; Wu, J.; Breitenbucher, J. G.; Chaplan, S. R.; Webb, M. Biochemical and Biological Properties of 4-(3-Phenyl-[1,2,4]thiadiazol-5-yl)piperazine-1-carboxylic Acid Phenylamide. A Mechanism-Based Inhibitor of Fatty Acid Amide Hydrolase. *Anesth. Analg.* **2009**, *108*, 316–329. (c) Keith, J. M.; Apocada, R.; Tichenor, M.; Xiao, W.; Jones, W.; Pierce, J.; Seierstad, M.; Palmer, J.; Webb, M.; Karbarz, M.; Scott, B.; Wilson, S.; Luo, L.; Wennerholm, M.; Chang, L.; Brown, S.; Rizzolio, M.; Rynberg, R.; Chaplan, S.; Breitenbucher, J. G. Aryl Piperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) in Rat, Dog, and Primate. *ACS Med. Chem. Lett.* **2012**, *3*, 823–827. (d) Tichenor, M. S.; Keith, J. M.; Jones, W. M.; Pierce, J. M.; Merit, J.; Hawryluk, N.; Seierstad, M.; Palmer, J. A.; Webb, M.; Karbarz, M. J.; Wilson, S. J.; Wennerholm, M. L.; Woestenborghs, F.; Beerens, D.; Luo, L.; Brown, S. M.; De Boeck, M.; Chaplan, S. R.; Breitenbucher, J. G. Heteroaryl Urea Inhibitors of Fatty Acid Amide Hydrolase: Structure–Mutagenicity Relationships for Arylamine Metabolites. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 7357–7362.
- (30) (a) Moore, S. A.; Nomikos, G. G.; Dickason–Chesterfield, A. K.; Sohober, D. A.; Schaus, J. M.; Ying, B. P.; Xu, Y. C.; Phebus, L.; Simmons, R. M.; Li, D.; Iyengar, S.; Felder, C. C. Identification of a High-Affinity Binding Site Involved in the Transport of Endocannabinoids (LY2183240). *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 17852–17857. (b) Alexander, J. P.; Cravatt, B. F. The Putative Endocannabinoid Transport Blocker LY2183240 Is a Potent Inhibitor of FAAH and Several Other Brain Serine Hydrolases. *J. Am. Chem. Soc.* **2006**, *128*, 9699–9704. (c) Butini, S.; Brindisi, M.; Gemma, S.; Minetti, P.; Cabri, W.; Gallo, G.; Vincenti, S.; Talamonti, E.; Borsini, F.; Caprioli, A.; Stasi, M. A.; Di Serio, S.; Ros, S.; Borrelli, G.; Maramai, S.; Fezza, F.; Campiani, G.; Maccarrone, M. Discovery of Potent Inhibitors of Human and Mouse Fatty Acid Amide Hydrolase. *J. Med. Chem.* **2012**, *55*, 6898–6915. (d) Kono, M.; Matsumoto, T.; Kawamura, T.; Nishimura, A.; Kiyota, Y.; Oki, H.; Miyazaki, J.; Igaki, S.; Behnke, C. A.; Shimojo, M.; Kori, M. Synthesis, SAR Study, and Biological Evaluation of a Series of Piperazine Ureas as Fatty Acid Amide Hydrolase (FAAH) Inhibitors. *Bioorg. Med. Chem.* **2013**, *21*, 28–41.
- (31) Minkila, A.; Myllymaki, M. J.; Saario, S. M.; Castillo-Melendez, J. A.; Koskinen, A. M. P.; Fowler, C. J.; Leppanen, J.; Nevalainen, T. The Synthesis and Biological Evaluation of para-Substituted Phenolic N-Alkyl Carbamates As Endocannabinoid Hydrolyzing Enzyme Inhibitors. *Eur. J. Med. Chem.* **2009**, *44*, 2294–3008.
- (32) Alexander, J. P.; Cravatt, B. F. Mechanism of Carbamate Inactivation of FAAH: Implications for the Design of Covalent Inhibitors and in Vivo Functional Probes for Enzymes. *Chem. Biol.* **2005**, *12*, 1179–1187.
- (33) Otrubova, K.; Boger, D. L. α -Ketoheterocycle-Based Inhibitors of Fatty Acid Amide Hydrolase. *ACS Chem. Neurosci.* **2012**, *3*, 340–348.
- (34) Boger, D. L.; Sato, H.; Lerner, A. E.; Hedrick, M. P.; Fecik, R. A.; Miyauchi, H.; Wilkie, G. D.; Austin, B. J.; Patricelli, M. P.; Cravatt, B. F. Exceptionally Potent Inhibitors of Fatty Acid Amide Hydrolase: The Enzyme Responsible for Degradation of Endogenous Oleamide and Anandamide. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 5044–5049.
- (35) Boger, D. L.; Miyauchi, H.; Hedrick, M. P. α -Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase: Carbonyl Group Modification and α -Substitution. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 1517–1520.
- (36) Boger, D. L.; Miyauchi, H.; Du, W.; Hardouin, C.; Fecik, R. A.; Cheng, H.; Hwang, I.; Hedrick, M. P.; Leung, D.; Acevedo, O.; Guimaraes, C. R. W.; Jorgensen, W. L.; Cravatt, B. F. Discovery of a Potent, Selective, and Efficacious Class of Reversible α -Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Effective as Analgesics. *J. Med. Chem.* **2005**, *48*, 1849–1856.
- (37) Leung, D.; Du, W.; Hardouin, C.; Cheng, H.; Hwang, I.; Cravatt, B. F.; Boger, D. L. Discovery of an Exceptionally Potent and Selective Class of Fatty Acid Amide Hydrolase Inhibitors Enlisting Proteome-Wide Selectivity Screening: Concurrent Optimization of Enzyme Inhibitor Potency and Selectivity. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 1423–1428.
- (38) Romero, F. A.; Hwang, I.; Boger, D. L. Delineation of a Fundamental α -Ketoheterocycle Substituent Effect for Use in the Design of Enzyme Inhibitors. *J. Am. Chem. Soc.* **2006**, *68*, 14004–14005.
- (39) Romero, F. A.; Du, W.; Hwang, I.; Rayl, T. J.; Kimball, F. S.; Leung, D.; Hoover, H. S.; Apocada, R. L.; Breitenbucher, B. J.; Cravatt, B. F.; Boger, D. L. Potent and Selective α -Ketoheterocycle-Based Inhibitors of the Anandamide and Oleamide Catabolizing Enzyme, Fatty Acid Amide Hydrolase. *J. Med. Chem.* **2007**, *50*, 1058–1068.
- (40) Hardouin, C.; Kelso, M. J.; Romero, F. A.; Rayl, T. J.; Leung, D.; Hwang, I.; Cravatt, B. F.; Boger, D. L. Structure–Activity Relationships of α -Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase. *J. Med. Chem.* **2007**, *50*, 3359–3368.
- (41) Kimball, F. S.; Romero, F. A.; Ezzili, C.; Garfinkle, J.; Rayl, T. J.; Hochstatter, D. G.; Hwang, I.; Boger, D. L. Optimization of α -Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase. *J. Med. Chem.* **2008**, *51*, 937–947.
- (42) Garfinkle, J.; Ezzili, C.; Rayl, T. J.; Hochstatter, D. G.; Hwang, I.; Boger, D. L. Optimization of the Central Heterocycle α -Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase. *J. Med. Chem.* **2008**, *51*, 4393–4403.
- (43) DeMartino, J. K.; Garfinkle, J.; Hochstatter, D. G.; Cravatt, B. F.; Boger, D. L. Exploration of a Fundamental Substituent Effect of α -Ketoheterocycle Enzyme Inhibitors: Potent and Selective Inhibitors of Fatty Acid Amide Hydrolase. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 5842–5846.
- (44) Ezzili, C.; Mileni, M.; McGlinchey, N.; Long, J. Z.; Kinsey, S. G.; Hochstatter, D. G.; Stevens, R. C.; Lichtman, A. H.; Cravatt, B. F.; Bilsky, E. J.; Boger, D. L. Reversible Competitive α -Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Containing Additional Conformational Constraints in the Acyl Side Chain: Orally Active, Long Acting Analgesics. *J. Med. Chem.* **2011**, *54*, 2805–2822.
- (45) (a) Lichtman, A. H.; Leung, D.; Shelton, C. C.; Saghatelian, A.; Hardouin, C.; Boger, D. L.; Cravatt, B. F. Reversible Inhibitors of Fatty Acid Amide Hydrolase that Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity. *J. Pharmacol. Exp. Ther.* **2004**, *311*, 441–448. (b) Chang, L.; Luo, L.; Palmer, J. A.; Sutton, S.; Wilson, S. J.; Barbier, A. J.; Breitenbucher, J. G.; Chaplan, S. R.; Webb, M. Inhibition of Fatty Acid Amide Hydrolase Produces Analgesia by Multiple Mechanisms. *Br. J. Pharmacol.* **2006**, *148*, 102–113. (c) Schlosburg, J. E.; Boger, D. L.; Cravatt, B. F.; Lichtman, A. H. Endocannabinoid Modulation of Scratching Response in an Acute Allergic Model: New Prospective Neural Therapeutic Target for Pruritus. *J. Pharmacol. Exp. Ther.* **2009**, *329*, 314–323. (d) Kinsey, S. G.; Long, J. Z.; O’Neal, S. T.; Abdulla, R. A.; Poklis, J. L.; Boger, D. L.; Cravatt, B. F.; Lichtman, A. H. Blockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic Pain. *J. Pharmacol. Exp. Ther.* **2009**, *330*, 902–910. (e) Booker, L.; Kinsey, S. G.; Abdullah, R. A.; Blankman, J. L.; Long, J. Z.; Boger, D. L.; Cravatt, B. F.; Lichtman, A. H. Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-3845 Acts in the Nervous System to Reverse LPS-Induced Tactile Allodynia in Mice. *Br. J. Pharmacol.* **2012**, *165*, 2485–2496.
- (46) For additional studies, see: (a) Wang, X.; Sarris, K.; Kage, K.; Zhang, D.; Brown, S. P.; Kolassa, T.; Surowy, C.; El Kouhen, O. F.; Muchmore, S. W.; Brioni, J. D.; Stewart, A. O. Synthesis and Evaluation of Benzothiazole-Based Analogues as Novel, Potent, and Selective Fatty Acid Amide Hydrolase Inhibitors. *J. Med. Chem.* **2009**, *52*, 170–180. (b) Gustin, D. J.; Ma, Z.; Min, X.; Li, Y.; Hedberg, C.; Guimaraes, C.; Wang, Z.; Kayser, F. Identification of Potent, Noncovalent Fatty Acid Amide Hydrolase (FAAH) Inhibitors. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 2492–2496. (c) Min, X.; Thibault, S. T.; Porter, A. C.; Gustin, D. J.; Carlson, T. J.; Xu, H.; Lindstrom, M.; Xu, G.; Uyeda, C.; Ma, Z.; Li, Y.; Kayser, F.; Walker, N. P. C.; Wang, Z. Discovery and Molecular Basis of Potent Noncovalent Inhibitors of Fatty Acid Amide Hydrolase (FAAH).

- Proc. Natl. Acad. Sci. U.S.A.* **2011**, *108*, 7379–7384. (d) Onnis, V.; Congiu, C.; Bjorklund, E.; Hempel, F.; Soderstrom, E.; Fowler, C. J. Synthesis and Evaluation of Paracetamol Esters as Novel Fatty Acid Amide Hydrolase Inhibitors. *J. Med. Chem.* **2010**, *53*, 2286–2298. (e) Vincent, F.; Nguyen, M. T.; Emerling, D. E.; Kelly, M. G.; Duncton, M. A. Mining Biologically-Active Molecules for Inhibitors of Fatty Acid Amide Hydrolase (FAAH): Identification of Phenmediphan and Amperozide as FAAH Inhibitors. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 6793–6796. (f) Wang, J. L.; Bowen, S. J.; Schweitzer, B. A.; Madsen, H. M.; McDonald, J.; Pelc, M. J.; Tenbrink, R. E.; Beidler, D.; Thorarensen, A. Structure-Based Design of Novel Irreversible FAAH Inhibitors. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 5970–5974. (g) Feledziak, M.; Michaux, C.; Urbach, A.; Labar, G.; Muccioli, G. G.; Lambert, D. M.; Marchand-Brynaert, J. Beta-Lactams Derived from a Carbapenem Chiron Are Selective Inhibitors of Human Fatty Acid Amide Hydrolase Versus Monoacylglycerol Lipase. *J. Med. Chem.* **2009**, *52*, 7054–7068. (h) Roughley, S. D.; Browne, H.; Macias, A. T.; Benwell, K.; Brooks, T.; D'Alessandro, J.; Daniels, Z.; Dugdale, S.; Francis, G.; Gibbons, B.; Hart, T.; Haymes, T.; Kennett, G.; Lightowler, S.; Matassova, N.; Mansell, H.; Merrett, A.; Misra, A.; Padfield, A.; Parsons, R.; Pratt, R.; Robertson, A.; Simmonite, H.; Tan, K.; Walls, S. B.; Wong, M. Fatty Acid Amide Hydrolase Inhibitors. 3: Tetrasubstituted Azetidine Ureas with in Vivo Activity. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 901–906. (i) Hart, T.; Macias, A. T.; Benwell, K.; Brooks, T.; D'Alessandro, J.; Dokurno, P.; Francis, G.; Gibbons, B.; Haymes, T.; Kennet, G.; Lightowler, S.; Mansell, H.; Matassova, N.; Misra, A.; Padfield, A.; Parsons, R.; Pratt, R.; Robertson, A.; Walls, S.; Wong, M.; Roughley, S. Fatty Acid Amide Hydrolase Inhibitors. Surprising Selectivity of Chiral Azetidine Ureas. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 4241–4244. (j) Wang, X.; Sarris, K.; Kage, K.; Zhang, D.; Brown, S. P.; Kolasa, T.; Surowy, C.; El Kouhen, O. F.; Muchmore, S. W.; Briono, J. D.; Stewart, A. O. Synthesis and Evaluation of Benzothiazole-based Analogues as Novel, Potent, and Selective Fatty Acid Amide Hydrolase Inhibitors. *J. Med. Chem.* **2009**, *52*, 170–180. (k) Minkkila, A.; Saario, S. M.; Kasanen, H.; Leppanene, J.; Poso, A.; Nevalainen, T. Discovery of Boronic Acids as Novel and Potent Inhibitors of Fatty Acid Amide Hydrolase. *J. Med. Chem.* **2008**, *51*, 7057–7060. (l) Urbach, A.; Muccioli, G. G.; Stern, E.; Lambert, D. M.; Marchand-Brynaert, J. 3-Alkenyl-2-azetidinones as Fatty Acid Amide Hydrolase Inhibitors. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4163–4167. (m) Muccioli, G. G.; Fazio, N.; Scriba, G. K. E.; Poppitz, W.; Cannata, F.; Poupaert, J. H.; Wouters, J.; Lambert, D. M. Substituted 2-Thioxoimidazolidin-4-ones and Imidazolidine-2,4-diones as Fatty Acid Amide Hydrolase Inhibitors Templates. *J. Med. Chem.* **2006**, *49*, 417–425. (n) Saario, S. M.; Poso, A.; Juvonen, R. O.; Jarvinen, T.; Salo-Ahen, O. M. H. Fatty Acid Amide Hydrolase Inhibitors from Virtual Screening of the Endocannabinoid System. *J. Med. Chem.* **2006**, *49*, 4650–4656. (o) Myllymaki, M. J.; Saario, S. M.; Kataja, A. O.; Castillo-Melendez, J. A.; Navalainen, T.; Juvonen, R. O.; Jarvinen, T.; Koskinen, A. M. P. Design, Synthesis, and in Vitro Evaluation of Carbamate Derivatives of 2-Benzoxazolyl- and 2-Benzothiazolyl-(3-hydroxyphenyl)-methanones as Novel Fatty Acid Amide Hydrolase Inhibitors. *J. Med. Chem.* **2007**, *50*, 4236–4242.
- (47) Mileni, M.; Johnson, D. S.; Wang, Z.; Everdeen, D. S.; Liimatta, M.; Pabst, B.; Bhattacharya, K.; Nugent, R. A.; Kamtekar, S.; Cravatt, B. F.; Ahn, K.; Stevens, R. C. Structure-Guided Inhibitor Design for Human FAAH by Interspecies Active Site Conversion. *Proc. Natl. Acad. Sci. U.S.A.* **2008**, *105*, 12820–12824.
- (48) Mileni, M.; Garfinkle, J.; DeMartino, J. K.; Cravatt, B. F.; Boger, D. L.; Stevens, R. C. Binding and Inactivation Mechanism of a Humanized Fatty Acid Amide Hydrolase by α -Ketoheterocycle Inhibitors Revealed from Cocystal Structures. *J. Am. Chem. Soc.* **2009**, *131*, 10497–10506.
- (49) Mileni, M.; Garfinkle, J.; Kimball, F. S.; Cravatt, B. F.; Stevens, R. C.; Boger, D. L. X-ray Crystallographic Analysis of α -Ketoheterocycle Inhibitors Bound to a Humanized Variant of Fatty Acid Amide Hydrolase. *J. Med. Chem.* **2010**, *53*, 230–240.
- (50) Mileni, M.; Garfinkle, J.; Ezzili, C.; Cravatt, B. F.; Stevens, R. C.; Boger, D. L. Fluoride-Mediated Capture of a Non-Covalent Bound State of a Reversible Covalent Enzyme Inhibitor: X-ray Crystallographic Analysis of an Exceptionally Potent α -Ketoheterocycle Inhibitor of Fatty Acid Amide Hydrolase. *J. Am. Chem. Soc.* **2011**, *133*, 4092–4100.
- (51) (a) McKinney, M. K.; Cravatt, B. F. Structure-Based Design of a FAAH Variant that Discriminates between the N-Acyl Ethanolamine and Taurine Families of Signaling Molecules. *Biochemistry* **2006**, *45*, 9016–9022. (b) Saghatelian, A.; McKinney, M. K.; Bandell, M.; Patapoutian, A.; Cravatt, B. F. A FAAH-Regulating Class of N-Acyl Taurines That Activates TRP Ion Channels. *Biochemistry* **2006**, *45*, 9007–9015. (c) Saghatelian, A.; Trauger, S. A.; Want, E. J.; Hawkins, E. G.; Suizdak, G.; Cravatt, B. F. Assignment of Endogenous Substrates to Enzymes by Global Metabolite Profiling. *Biochemistry* **2004**, *43*, 14332–14339.
- (52) Otrubova, K.; Brown, M.; McCormick, M. S.; Han, G. W.; O'Neal, S. T.; Cravatt, B. F.; Stevens, R. C.; Lichtman, A. H.; Boger, D. L. Rational Design of Fatty Acid Amide Hydrolase Inhibitors That Act by Covalently Bonding to Two Active Site Residues. *J. Am. Chem. Soc.* **2013**, *135*, 6289–6399.
- (53) Farina, V.; Krishnamurthy, V.; Scott, W. J. The Stille Reaction. *Org. React.* **1997**, *50*, 1–652.
- (54) Dess, D. B.; Martin, J. C. A Useful 12-I-5 Triacetoxypiperidine (the Dess–Martin Periodinane) for the Selective Oxidation of Primary or Secondary Alcohols and a Variety of Related 12-I-5 Species. *J. Am. Chem. Soc.* **1991**, *113*, 7277–7287.
- (55) Patricelli, M. P.; Lashuel, H. A.; Giang, D. K.; Kelly, J. W.; Cravatt, B. F. Comparative Characterization of a Wild Type and Transmembrane Domain-Deleted Fatty Acid Amide Hydrolase: Identification of the Transmembrane Domain as a Site for Oligomerization. *Biochemistry* **1998**, *37*, 15177–15187.
- (56) As controls, inhibitors **2** and **3** were evaluated at the same time and also displayed reversible, competitive enzyme inhibition upon Lineweaver–Burk kinetic analysis (see the Supporting Information).
- (57) (a) Evans, M. J.; Cravatt, B. F. Mechanism-Based Profiling of Enzyme Families. *Chem. Rev.* **2006**, *106*, 3279–3301. (b) Liu, Y. S.; Patricelli, M. P.; Cravatt, B. F. Activity-Based Protein Profiling: The Serine Hydrolases. *Proc. Natl. Acad. Sci. U.S.A.* **1999**, *96*, 14694–14699. (c) Kidd, D.; Liu, Y. S.; Cravatt, B. F. Profiling Serine Hydrolase Activities in Complex Proteomes. *Biochemistry* **2001**, *40*, 4005–4015.
- (58) Long, J. Z.; Nomura, D. K.; Cravatt, B. F. Characterization of Monoacylglycerol Lipase Inhibition Reveals Differences in Central and Peripheral Endocannabinoid Metabolism. *Chem. Biol.* **2009**, *16*, 744–753.
- (59) Guimarães, C. R. W.; Boger, D. L.; Jorgensen, W. L. Elucidation of Fatty Acid Amide Hydrolase Inhibition by Potent α -Ketoheterocycle Derivatives from Monte Carlo Simulations. *J. Am. Chem. Soc.* **2005**, *127*, 17377–17384.